Vitamins K and D status in stages 3-5 chronic kidney disease
- PMID: 20167683
- PMCID: PMC2849681
- DOI: 10.2215/CJN.06420909
Vitamins K and D status in stages 3-5 chronic kidney disease
Abstract
Background and objectives: Vitamin K, vitamin K-dependent proteins, and vitamin D may be involved in the regulation of calcification in chronic kidney disease (CKD).
Design, setting, participants, & measurements: Vitamin K and D status was measured as dietary intake, plasma phylloquinone, serum percent uncarboxylated osteocalcin (%ucOC), proteins induced by vitamin K absence (PIVKA-II), Vitamin K Epoxide Reductase single-nucleotide polymorphism, apolipoprotein E genotype, and plasma 25-hydroxyvitamin D (25(OH)D) in 172 subjects with stage 3 to 5 CKD. Nutritional status was determined by subjective global assessment.
Results: Subclinical vitamin K deficiency criteria was met by 6% (phylloquinone), 60% (%ucOC), and 97% (PIVKA-II) of subjects, whereas 58.3% and 8.6% had 25(OH)D insufficiency and deficiency, respectively. Dietary vitamin K intake was associated with higher phylloquinone and lower PIVKA-II. There were positive correlations between phylloquinone and the presence of stable weight, and the absence of subcutaneous fat loss or muscle wasting. 25(OH)D levels were positively associated with stable weight and albumin (P < 0.001). PIVKA-II levels were associated with apolipoprotein E genotype. Higher %ucOC and lower 25(OH)D were similarly associated with CKD stage, parameters of mineral metabolism, and urine albumin to creatinine ratio.
Conclusions: These data indicate that a suboptimal vitamin K and D status is prevalent in patients with CKD. Sufficiency of both vitamins K and D was similarly predicted by measures of overall improved nutritional status. Proteinuria was associated with both a suboptimal vitamin D status as well as worse peripheral vitamin K status.
References
-
- Garland JS, Holden RM, Groome PA, Lam M, Nolan RL, Morton AR, Pickett W: Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. Am J Kidney Dis 52: 849–858, 2008 - PubMed
-
- Shanahan CM: Vascular calcification. Curr Opin Nephrol Hypertens 14: 361–367, 2005 - PubMed
-
- Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De Mey JG, Vermeer C: Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 289: 485–490, 2001 - PubMed
-
- Proudfoot D, Shanahan CM: Molecular mechanisms mediating vascular calcification: Role of matrix Gla protein. Nephrology 11: 455–461, 2006 - PubMed
-
- Holden RM, Iliescu E, Morton AR, Booth SL: Vitamin K status of Canadian peritoneal dialysis patients. Perit Dial Int 28: 415–418, 2008 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous